Skip to Content

Potiga (ezogabine) Disease Interactions

There are 8 disease interactions with Potiga (ezogabine):

Moderate

Antiepileptics (Includes Potiga) ↔ Suicidal Tendency

Moderate Potential Hazard, Moderate plausibility

Applies to: Depression, Psychosis

Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs across multiple indications in either monotherapy or adjunctive therapy for a median treatment duration of 12 weeks (up to a maximum of 24 weeks) showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo. The estimated rate of suicidal behavior or ideation among 27,863 AED-treated patients was 0.43%, compared to 0.24% for 16,029 placebo-treated patients, representing an increase of approximately one case for every 530 patients treated. There were four suicides in AED-treated patients and none in placebo-treated patients, although the number is too small to establish any causal relationship. The increased risk of suicidal thoughts or behavior was observed as early as one week after starting AEDs and persisted for the duration of treatment assessed. The risk did not vary substantially by age (5 to 100 years) in the clinical trials analyzed. Therapy with AEDs should be administered cautiously in patients with depression or other psychiatric disorders. The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior. Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior. For clinically significant or persistent symptoms, a dosage reduction or treatment withdrawal should be considered. If patients have symptoms of suicidal ideation or behavior, treatment should be discontinued.

Moderate

Ezogabine (Includes Potiga) ↔ Alcoholism

Moderate Potential Hazard, Moderate plausibility

Applies to: Acute Alcohol Intoxication

The use ezogabine with alcohol increases the systemic exposure to ezogabine. Patients should be advised of possible worsening of dose-related adverse reactions if they take ezogabine with alcohol.

Moderate

Ezogabine (Includes Potiga) ↔ Hepatic Impairment

Moderate Potential Hazard, Moderate plausibility

Applies to: Liver Disease

No dosage adjustment is recommended in patients with mild hepatic impairment. Dosage adjustment is recommended in patients with moderate or severe hepatic impairment. Close monitoring is recommended.

Moderate

Ezogabine (Includes Potiga) ↔ Hyperbilirubinemia

Moderate Potential Hazard, Moderate plausibility

Applies to: Hyperbilirubinemia

Ezogabine has been shown to interfere with clinical laboratory assays of both serum and urine bilirubin, which can result in falsely elevated readings.

Moderate

Ezogabine (Includes Potiga) ↔ Qt Prolongation

Moderate Potential Hazard, Moderate plausibility

Applies to: Hypokalemia, Electrolyte Abnormalities, Heart Disease

QT prolongation was observed in patients treated with ezogabine. It is recommended to monitor the QT interval when ezogabine is used with medicines known to increase QT interval and in patients with known prolonged QT interval, congestive heart failure, ventricular hypertrophy, hypokalemia, or hypomagnesemia.

Moderate

Ezogabine (Includes Potiga) ↔ Renal Impairment

Moderate Potential Hazard, Moderate plausibility

Applies to: Renal Dysfunction

Dosage adjustment is recommended in patients with creatinine clearance <50 mL/min or patients with end-stage renal disease receiving hemodialysis. A supplemental dose is recommended immediately following hemodialysis. Close monitoring is recommended.

Moderate

Ezogabine (Includes Potiga) ↔ Retinal Abnormalities

Moderate Potential Hazard, Moderate plausibility

Applies to: Retinal Disorder

The use of ezogabine can cause abnormalities of the retina. Patients should have baseline ophthalmologic testing by an ophthalmic professional and follow-up testing as clinically indicated. Patients who cannot be monitored should not be treated with ezogabine. The ophthalmologic monitoring program should include visual acuity testing, dilated fundus photography, and optical coherence tomography. Additional testing may include fluorescein angiograms, perimetry, and electroretinograms. If retinal pigmentary abnormalities or vision changes are detected, ezogabine should be discontinued unless no other suitable treatment options are available and the benefits of treatment outweigh the potential risk of vision loss.

Moderate

Ezogabine (Includes Potiga) ↔ Urinary Retention

Moderate Potential Hazard, Moderate plausibility

Applies to: Urinary Retention

The use of ezogabine may cause urinary retention. A comprehensive evaluation of urologic symptoms should be conducted prior to and during treatment with ezogabine as clinically indicated. It is recommended to monitor closely for urologic symptoms in patients at risk.

Potiga (ezogabine) drug Interactions

There are 792 drug interactions with Potiga (ezogabine)

Potiga (ezogabine) alcohol/food Interactions

There is 1 alcohol/food interaction with Potiga (ezogabine)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2017 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide